Back to Search
Start Over
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
- Source :
- Advances in Therapy
- Publication Year :
- 2021
- Publisher :
- Springer Healthcare, 2021.
-
Abstract
- Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US) Food and Drug Administration (FDA) for the management of ES-SCLC following progression after first-line treatment with etoposide plus a platinum derivative (EP; carboplatin preferred). With the most recent approval of EP plus a programmed death ligand 1 (PD-L1) inhibitor, there are now more therapeutic options for managing ES-SCLC. A number of novel agents have emerging data for activity in relapsed ES-SCLC, and single-agent lurbinectedin (an alkylating drug and selective inhibitor of oncogenic transcription and DNA repair machinery in tumor cells) has conditional FDA approval for use in this patient population. Trilaciclib, a short-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, has also been recently approved as a supportive intervention for use prior to an EP or a topotecan-containing regimen to diminish the incidence of chemotherapy-induced myelosuppression. The current review is based on a recent expert roundtable discussion and summarizes current therapeutic agents and emerging data on newer agents and biomarkers. It also provides evidence-based clinical considerations and a treatment decision tool for oncologists treating patients with relapsed ES-SCLC. This paper discusses the importance of various factors to consider when selecting a second-line treatment option, including prior first-line treatment, available second-line treatment options, tumor platinum sensitivity, and patient characteristics (such as performance status, comorbidities, and patient-expressed and perceived values).
- Subjects :
- Drug
Oncology
Lurbinectedin
medicine.medical_specialty
Durvalumab
Lung Neoplasms
media_common.quotation_subject
Review
Etoposide/platinum
Relapsed
chemistry.chemical_compound
Atezolizumab
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
Pharmacology (medical)
Pyrroles
Etoposide
media_common
Performance status
Small cell lung cancer
business.industry
General Medicine
Small Cell Lung Carcinoma
Carboplatin
Regimen
Pyrimidines
chemistry
Topotecan
Immunotherapy
Neoplasm Recurrence, Local
business
Biomarkers
medicine.drug
Extensive-stage
Subjects
Details
- Language :
- English
- ISSN :
- 18658652 and 0741238X
- Database :
- OpenAIRE
- Journal :
- Advances in Therapy
- Accession number :
- edsair.doi.dedup.....d0a718a35b9f237556d6a1eb41a7a2e3